Alkem Laboratories Q4FY22 PAT down -55.17% at Rs108 crore on higher input costs and tax outgo

15 May 2022 , 06:07 PM

Alkem Laboratories Ltd reported 13.31% growth in sales revenues yoy for the Q4FY22 quarter on consolidated basis at Rs2,484 crore. On a sequential basis, revenues were lower for the quarter by -5.16%.

For full year FY22, the revenues were higher by 19.95% at Rs10,634 crore. For Q4FY22, the India sales were up 16.7% at Rs1,719 crore while the global sales were 7.3% at Rs741 crore.

The US business faced significant pricing pressures leading to subdued sales growth overall. In fact for the full year, sales were up 29% for India but just over 2% for global sales. Net cash from operations saw spike in inventories and receivables.

The consolidated net profit for Q4FY22 was down -55.17% at Rs108 crore while it was down on a sequential basis by -79.53.

The fall in profits was largely on account of significant pricing pressures in the US markets. In India, growth was led by anti-infectives, vitamins and pain management vert9icals. Net margins stood at 4.33% in Q4FY22 quarter compared to 10.95% in Q4FY21.

NPM was lower sequentially against 20.07% in Q3FY22. However, for Q4, EBITDA margins improved by 30 bps to 13.6%. R&D expenses were 6.6% of revenues.

Financial highlights for Mar-22 compared yoy and sequentially

	Alkem Laboratories
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 2,484	₹ 2,192	13.31%	₹ 2,619	-5.16%
Net Profit (Rs cr)	₹ 108	₹ 240	-55.17%	₹ 526	-79.53%
Diluted EPS (Rs)	₹ 8.00	₹ 20.07		₹ 43.96
Net Margins	4.33%	10.95%		20.07%